BNP Paribas Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$169M Sell
2,104,677
-80,976
-4% -$6.68M 0.2% 109
2025
Q4
$186M Buy
2,185,653
+436,200
+25% +$35.8M 0.21% 92
2025
Q3
$136M Buy
1,749,453
+134,850
+8% +$10.5M 0.35% 53
2025
Q2
$126M Buy
1,614,603
+272,762
+20% +$20.3M 0.31% 65
2025
Q1
$97.3M Buy
1,341,841
+224,531
+20% +$16.1M 0.26% 91
2024
Q4
$82.7M Buy
1,117,310
+73,549
+7% +$5.15M 0.21% 109
2024
Q3
$68.9M Sell
1,043,761
-6,628
-0.6% -$482K 0.17% 134
2024
Q2
$97M Sell
1,050,389
-130,079
-11% -$11.5M 0.25% 88
2024
Q1
$113M Sell
1,180,468
-36,645
-3% -$3.08M 0.3% 72
2023
Q4
$92.8M Sell
1,217,113
-338,074
-22% -$23.5M 0.26% 99
2023
Q3
$108M Sell
1,555,187
-132,796
-8% -$10.7M 0.33% 70
2023
Q2
$159M Buy
1,687,983
+374,985
+29% +$32.6M 0.49% 40
2023
Q1
$109M Buy
1,312,998
+100,656
+8% +$7.91M 0.38% 57
2022
Q4
$90.5M Sell
1,212,342
-38,601
-3% -$2.97M 0.32% 73
2022
Q3
$103M Buy
1,250,943
+36,467
+3% +$3.51M 0.41% 52
2022
Q2
$115M Buy
1,214,476
+174,144
+17% +$18M 0.44% 44
2022
Q1
$122M Buy
1,040,332
+195,893
+23% +$22M 0.43% 46
2021
Q4
$109M Sell
844,439
-83,548
-9% -$9.75M 0.37% 58
2021
Q3
$105M Sell
927,987
-69,147
-7% -$7.89M 0.39% 55
2021
Q2
$103M Buy
997,134
+75,623
+8% +$7.13M 0.37% 56
2021
Q1
$77.1M Buy
921,511
+28,930
+3% +$2.45M 0.32% 72
2020
Q4
$81.4M Buy
892,581
+90,085
+11% +$7.47M 0.38% 57
2020
Q3
$64.1M Sell
802,496
-153,703
-16% -$12M 0.36% 61
2020
Q2
$66.1M Sell
956,199
-16,392
-2% -$1.16M 0.45% 48
2020
Q1
$61.1M Buy
972,591
+212,334
+28% +$15.3M 0.52% 34
2019
Q4
$59.1M Sell
760,257
-27,570
-3% -$2.15M 0.4% 49
2019
Q3
$57.8M Buy
787,827
+26,592
+3% +$1.87M 0.44% 45
2019
Q2
$46.9M Buy
761,235
+107,424
+16% +$6.5M 0.38% 63
2019
Q1
$41.7M Sell
653,811
-100,806
-13% -$5.75M 0.35% 60
2018
Q4
$37.8M Sell
754,617
-53,604
-7% -$2.71M 0.35% 62
2018
Q3
$46.9M Sell
808,221
-2,262
-0.3% -$111K 0.36% 67
2018
Q2
$39.3M Sell
810,483
-309,855
-28% -$14.5M 0.33% 71
2018
Q1
$52.1M Sell
1,120,338
-467,826
-29% -$20.3M 0.44% 36
2017
Q4
$59.7M Sell
1,588,164
-37,935
-2% -$1.39M 0.51% 28
2017
Q3
$59.2M Buy
1,626,099
+230,262
+16% +$8.78M 0.5% 36
2017
Q2
$55M Sell
1,395,837
-396,666
-22% -$14.5M 0.49% 37
2017
Q1
$56.2M Buy
1,792,503
+378,264
+27% +$11.8M 0.52% 38
2016
Q4
$44.2M Buy
1,414,239
+477,489
+51% +$15.5M 0.42% 53
2016
Q3
$37.6M Sell
936,750
-647,157
-41% -$24.4M 0.32% 66
2016
Q2
$52.7M Buy
1,583,907
+156,168
+11% +$5.34M 0.44% 48
2016
Q1
$42M Buy
1,427,739
+745,341
+109% +$20.6M 0.36% 66
2015
Q4
$18M Buy
682,398
+302,406
+80% +$7.85M 0.15% 176
2015
Q3
$9M Sell
379,992
-13,326
-3% -$322K 0.08% 327
2015
Q2
$9.34M Buy
393,318
+221,394
+129% +$5M 0.08% 347
2015
Q1
$4.08M Buy
171,924
+67,698
+65% +$1.52M 0.03% 548
2014
Q4
$2.21M Buy
104,226
+11,208
+12% +$225K 0.02% 599
2014
Q3
$1.58M Buy
93,018
+1,002
+1% +$15.8K 0.01% 659
2014
Q2
$1.32M Sell
92,016
-576
-0.6% -$7.81K 0.01% 725
2014
Q1
$1.15M Buy
92,592
+44,742
+94% +$516K 0.01% 746
2013
Q4
$524K Sell
47,850
-4,626
-9% -$52.1K ﹤0.01% 766
2013
Q3
$609K Buy
+52,476
New +$614K ﹤0.01% 745

Other funds holding EW

BNP Paribas Asset Management's EW Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Edwards Lifesciences (EW) stake by 3.7% in Q1 2026, selling an estimated $6.68M and leaving 2,104,677 shares worth $169M. The position accounts for 0.2% of the portfolio, ranked #109.

BNP Paribas Asset Management first reported a position in EW in Q3 2013 and has held it in 51 quarters since. The position peaked at $186M in Q4 2025. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • BNP Paribas Asset Management held 2,104,677 shares of Edwards Lifesciences worth $169M as of Q1 2026.
  • BNP Paribas Asset Management sold 80,976 Edwards Lifesciences shares in Q1 2026, an estimated $6.68M.
  • Edwards Lifesciences made up 0.2% of BNP Paribas Asset Management's portfolio in Q1 2026, its #109 holding.
  • BNP Paribas Asset Management first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 51 quarters since.
  • BNP Paribas Asset Management's Edwards Lifesciences position peaked at $186M in Q4 2025.
  • 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.